The principal hydroxy-metabolites of benzene - phenol, catechol and hydroquinone - possess characteristics and produce toxicity similar to those reported for certain inhibitors of microtubule polymerization. In this study we examined the effects of phenol, catechol and hydroquinone on purified microtubule polymerization and the decay of tubulin-colchicine binding activity. Hydroquinone, but not catechol or phenol, inhibited microtubule polymerization and accelerated the decay of tubulin-colchicine binding activity. The latter effect was shown to be dependent on the concentration of GTP. Hydroquinone did not directly complex with GTP or ATP but bound to the high molecular weight fraction of tubulin. concentration ratios of hydroquinone to tubulin resulting in altered activity were low, suggesting a specific interaction, presumably at the tubulin-GTP binding site. The acceleration of tubulin-colchicine binding activity decay was completely prevented under anaerobic conditions, indicative of an oxidative mechanism. These studies suggest that hydroquinone, which auto-oxidizes, may interfere with microtubule function, nucleotide binding or both and that this mechanism may be involved in eliciting the wide range of cytoskeletal-related abnormalities observed in cells exposed to benzene in vivo or its metabolites in vitro.
Clinical pathology testing in nonclinical toxicity and safety studies is an important part of safety assessment. In recent years, clinical laboratory testing has rapidly expanded and improved. Some government regulatory agencies provide guidelines for clinical pathology testing in nonclinical toxicity and safety studies. To improve these testing guidelines and the resultant safety assessments, the American Association for Clinical Chemistry's Division of Animal Clinical Chemistry and the American Society for Veterinary Clinical Pathology formed a joint committee to provide expert recommendations for clinical pathology testing of laboratory species involved in subchronic and chronic nonclinical toxicity and safety studies. These recommendations include technical recommendations on blood collection techniques and hematology, serum chemistry, and urinalysis tests.
The effect of carcinogen treatment on gamma-glutamyl transpeptidase (GGT)-mediated hydrolysis of GSH to glutamate and cysteinylglycine in the blood and bile compartments was investigated in livers perfused in situ. Treatment of rats with 40 p.p.m. diethylnitrosamine (DEN) in the drinking water or 0.02% 2-acetylaminofluorene (AAF) in the diet for 50-60 days increased GGT activity in liver homogenates by 100 and 800% respectively. Bile flow and the sum of glutamate and glutathione (GSH) efflux into the bile of perfused livers was not affected by carcinogen treatment. However, the ratio of GSH to glutamate in bile was 2.1, 1.1 and 0.2 in livers from control, DEN- and AAF-treated rats respectively. Pretreatment with L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT125) decreased GGT activity in liver homogenates by about 85% and elevated the ratio of GSH to glutamate in the bile to 3.2 in all groups. Thus, the hydrolysis of GSH to glutamate in the bile of perfused livers correlated with the degree of induction of GGT by DEN and AAF treatments. Exogenous GSH (10 microM) infused into the portal vein of perfused livers from control, DEN- and AAF-treated rats was recovered completely in the effluent perfusate. Pretreatment with AT125 had no effect on the recovery of exogenous GSH in the effluent perfusate. Thus, metabolism of GSH in the blood space was not detected after short-term carcinogen treatment. To increase the possible hydrolysis of GSH in the perfusate, rats were treated for 130-180 days with DEN and GSH (60 microM) was infused into the hepatic artery of livers perfused simultaneously via the hepatic artery and portal vein. Only 50% of the infused GSH was recovered in the effluent perfusate of perfused livers from DEN-treated rats. In contrast, significantly more GSH (80-90%) was recovered from livers from control rats or DEN-treated rats that had received AT125 pretreatment. In addition AT125 pretreatment increased the basal rates of GSH efflux in livers from DEN-treated rats. Thus, DEN-induced GGT metabolizes GSH entering the liver via the hepatic artery. Furthermore, GGT may act to decrease the net efflux of GSH from perfused livers by causing the intraorgan recycling of GSH and its constituent amino acids.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.